



SUB-CELLULAR LOCALIZATION OF THE PENA β-LACTAMASE IN 





Linnell B. Randall 




In partial fulfillment of the requirements  
For the Degree of Master of Science 
Colorado State University 





 Advisor:  Herbert P. Schweizer 
 Brad R. Borlee 





SUB-CELLULAR LOCALIZATION OF THE PENA β-LACTAMASE 
IN BURKHOLDERIA PSEUDOMALLEI 
 
 Burkholderia pseudomallei, a Gram-negative soil bacterium found in tropical regions, is 
the etiologic agent of melioidosis.  B. pseudomallei is intrinsically resistant to many antibiotics, 
and melioidosis treatment involves prolonged antibiotic therapy.  PenA, a chromosomal β-
lactamase in B. pseudomallei, confers resistance to many β-lactams.  Point mutations in penA 
leading to PenA amino acid changes can cause resistance to ceftazidime and amoxicillin-
clavulanate, which can result in treatment failure.  Typically β-lactamase enzymes are found in 
the periplasm of Gram-negative bacteria.  Previous studies have shown that PenA is secreted via 
the twin arginine translocase (Tat) system, but failed to demonstrate periplasmic localization. 
 The purpose of this study was to determine the sub-cellular localization of PenA in B. 
pseudomallei.  Using alkaline phosphatase as a periplasmic marker, we optimized a method for 
extracting periplasmic proteins from B. pseudomallei.  Through subcellular fractionations, 
immunoblotting, and colorimetric enzyme assays, we have shown that PenA does not localize to 
the periplasm.  Rather, it is present in a detergent-soluble fraction of the cellular membranes.  
Further experiments including site-directed mutagenesis, metabolic labeling with 14C-palmitate, 
globomycin treatment, and mass spectrometry indicate that PenA is likely a lipoprotein with 
post-translational lipid modification of the cysteine residue at position 23.  This work implicates 
PenA as the first example of a β-lactamase that is a Tat-secreted lipoprotein, and provides a 
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1.1 Burkholderia pseudomallei and melioidosis 
Burkholderia pseudomallei is a saprophytic Gram-negative rod. Considered to be 
endemic in Southeast Asia and Northern Australia, it is found throughout tropical regions of the 
world (Figure 1.1) (1).  As the causative agent of melioidosis, B. pseudomallei has been 
designated a Tier 1 Select Agent by the United States Centers for Disease Control and 
Prevention, due to its low infectious dose, intrinsic antibiotic resistance, and relatively high 
morbidity and mortality (2, 3). 
The genome of B. pseudomallei is very large and highly plastic, with two chromosomes 
of approximately 3.2 and 4.1 million base pairs encoding some 5,800 genes (4).  With this large 
coding capacity, B. pseudomallei is able to survive and thrive in a diverse set of environments, 
from its natural reservoir in the soil to a wide variety of mammalian hosts (5).  Virulence factors 
include three type III secretion systems (6), six type VI secretion systems (7), capsular 
polysaccharide (8), lipopolysaccharide (9), flagella (10), multiple quorum sensing systems (11), 
at least one cytotoxin (12), and a variety of other components that allow B. pseudomallei to 
infect host organisms, survive intracellularly, and cause disease. 
 B. pseudomallei infection can result from percutaneous inoculation, inhalation, or 
ingestion of contaminated food or water (13).  Melioidosis has been referred to as “The Great 
Mimicker,” reflecting the wide variety of clinical manifestations and their resemblance to other 
diseases.  The most common of these manifestations are pneumonia, septicemia, skin abscesses, 
and genitourinary infection (14). Melioidosis treatment is lengthy and involves two phases of 
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antibiotic treatment.  The first, intensive phase consists of at least 10-14 days of intravenous 
ceftazidime, meropenem, or imipenem.  This is followed by 3-6 months of oral eradication 
therapy with co-trimoxazole or amoxicillin-clavulanic acid (13). 
Figure 1.1 Geographic distribution of melioidosis.  B. pseudomallei has been identified in 
environmental samples from tropical regions around the world, especially in Southeast Asia and 
Northern Australia.  Adapted from Limmathurotakul et. al. (1). 
 
1.2 Antibiotic resistance mechanisms 
 Bacteria possess a variety of antibiotic resistance mechanisms, as illustrated in Figure 1.2 
(15).  Drugs can be prevented from entering the cell by physical exclusion, or effluxed out of the 
cell by active transport.  Within a bacterial cell, drugs can be sequestered to block their activity, 




the effects of antibiotics by overproducing, altering, or deleting the drug target, or by bypassing 
the susceptible enzyme or metabolic pathway with a resistant alternative.  A majority of these 
antibiotic resistance mechanisms have been demonstrated in B. pseudomallei, and the extensive 
intrinsic resistance of this organism dictates the limited number of drugs available to treat 
melioidosis (15). 
The very nature of the Gram-negative cell envelope provides a significant permeability 
barrier for drugs entering the cell.  In addition, the lipid A moiety of lipopolysaccharide in B. 
pseudomallei has a 4-amino-4-deoxy-L-arabinose modification, which reduces the negative 
charge on the exterior of the cell, protecting the bacteria from cationic antimicrobial peptides 
such as polymyxin B (16). 
 Efflux pumps provide an important means of antibiotic resistance in B. pseudomallei, 
whose genome encodes up to ten resistance nodulation and cell division (RND) family multidrug 
efflux pumps (4), though only three have been characterized to date.  Among these, the AmrAB-
OprA pump has been shown to efflux aminoglycosides such as gentamycin, kanamycin, 
streptomycin, and spectinomycin, and macrolides such as erythromycin, clarithromycin, and 
clindamycin, providing high levels of intrinsic resistance to those drug families (17).  
Fluoroquinolones and tetracyclines are also effluxed by AmrAB-OprA, but to a much lesser 
extent (18).  The BpeAB-OprB efflux pump provides low level intrinsic resistance to macrolides, 
fluoroquinolones, tetracyclines, and chloramphenicol (18).  Finally, the BpeEF-OprC efflux 
pump is of clinical significance due to its ability to efflux chloramphenicol, trimethoprim, 
tetracyclines, and fluoroquinolones (19 and Podnecky, N. et al., unpublished data). 
 While target deletion is a fairly unusual form of antibiotic target modification, the 
deletion of penicillin-binding protein 3 in B. pseudomallei has been shown to confer resistance to 
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ceftazidime (20).  Although the resulting strains have severe growth defects in laboratory culture 
media, ceftazidime-resistant strains lacking PBP3 have been isolated from six Thai melioidosis 
patients following ceftazidime treatment (20).  Thus, this example of target deletion is an 
important means of acquired ceftazidime resistance in B. pseudomallei which can result in 
melioidosis treatment failure. 
 Finally, another important β-lactam resistance mechanism in B. pseudomallei involves 
enzymatic inactivation by the PenA β-lactamase.  PenA is responsible for both intrinsic 
resistance to older β-lactam antibiotics such as ampicillin and carbenicillin, and acquired 
resistance to ceftazidime and amoxicillin-clavulanate through amino acid changes or increased 
transcription of penA (21).  Of particular clinical concern, there have been several documented 





Figure 1.2 Bacterial antibiotic resistance mechanisms.  Antibiotic resistance mechanisms 
include drug exclusion or efflux, sequestration or enzymatic inactivation of the drug, metabolic 









1.3 β-lactam antibiotics 
 Of the five antibiotics recommended for treatment of melioidosis (13), four are β-lactam 
compounds.  Ceftazidime is a third generation cephalosporin (27), meropenem and imipenem are 
carbapenems (28, 29), and amoxicillin is a semisynthetic penicillin (30) which is administered in 
combination with the β-lactamase inhibitor clavulanic acid (31). 
 Penicillins, cephalosporins, and carbapenems comprise three major groups of β-lactam 
compounds.  All contain a characteristic four-membered β-lactam ring which is fused with a 
five-membered sulfur-containing ring in penicillins, a six-membered ring in cephalosporins, or 
an unsaturated 5-membered ring in carbapenems (Figure 1.3). 
 β-lactam antibiotics bind and inhibit penicillin-binding proteins (DD-transpeptidases), 
which are responsible for cross-linking the peptidoglycan of bacterial cell walls.  This weakening 
of the cell wall generally results in a bactericidal effect on actively growing cells (32). 
Figure 1.3 Examples of β-lactam structures.  (a) Amoxicillin is a penicillin, (b) ceftazidime is 
a cephalosporin, and (c) meropenem is a carbapenem. β-lactam rings are circled in red. 
 
1.4 β-lactamases 
 Just as antibiotic compounds such as β-lactams are natural products of microorganisms, 




to avoid the killing effects of β-lactam antibiotics by hydrolyzing the β-lactam ring, thereby 
inactivating the drug. More than 300 β-lactamases have been identified across bacterial genera 
(33). 
The Ambler classification system divides β-lactamases into four groups based on 
sequence. Classes A, C, and D all have a serine residue in the active site, while the more 
distantly related Class B enzymes are metallo β-lactamases requiring zinc for hydrolytic activity 
(33).  Different sub-groups of Class A enzymes can cleave penicillins and cephalosporins, and a 
few are able to hydrolyze carbapenems.  They are generally susceptible to inhibitors such as 
clavulanic acid, although enzymes with amino acid changes making them resistant to inhibition 
are emerging (34).  Class B β-lactamases are able to cleave most β-lactam structures, and while 
they are inhibited by metal chelators such as EDTA, they are resistant to traditional inhibitors 
such as clavulanic acid (33).  Class C enzymes are cephalosporinases, which are resistant to 
clavulanic acid inhibition (34), and have only been identified in Gram-negative organisms (33).  
Class D β-lactamases, which can usually be inhibited by clavulanic acid, are characterized by 
their efficient hydrolysis of oxacillin (32) as well as other penicillins (34). 
 
1.5 Sec and Tat secretion systems 
 In Gram-negative bacteria, β-lactamase enzymes are generally found in the periplasmic 
space between the inner and outer membranes.  There, they are able to cleave β-lactam 
antibiotics, preventing them from interfering with peptidoglycan cross-linking.  The TEM-1 β-
lactamase from E. coli has been well-characterized as a Sec-secreted periplasmic protein, and its 
periplasmic activity has been exploited in a variety of gene-fusion reporter systems (35-40). 
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 The majority of β-lactamases tested, including TEM-1, have been shown to be 
transported across the cytoplasmic membrane by the general secretary (Sec) system (41).  
However, there are several examples of β-lactamases that are secreted by the alternative twin 
arginine translocase (Tat) system, including PenA from B. pseudomallei (21, 42-44). 
The Sec system transports unfolded proteins across the cytoplasmic membrane, while the 
Tat system generally transports pre-folded proteins, often in complex with cofactors (45).  Pre-
proteins in the cytoplasm are targeted for Sec or Tat transport by N-terminal signal sequences.  
Both Sec and Tat signal sequences are tripartite, comprised of a positively charged N-terminal 
region, a hydrophobic core, and a C-terminal region containing a cleavage site.  Tat signals are 
longer and less hydrophobic than their Sec counterparts, and contain a characteristic pair of 
arginine residues in the N-terminal region, though some TAT signal sequences contain only one 
arginine (46). 
 Proteins destined for Sec secretion are either bound by the signal recognition particle 
(SRP) during translation, or post-translationally by the SecB chaperone.  As is depicted in Figure 
1.4, SRP or SecB targets the new polypeptide to the SecA-SecYEG complex in the cytoplasmic 
membrane, where the SecA motor hydrolyzes ATP to drive the protein through the channel 
formed by SecYEG (45).  The Tat secretion system, illustrated in Figure 1.5, involves a larger 
channel comprised of the TatABC proteins (though some organisms lack TatA or TatB).  The 
protein to be secreted is recognized by TatC, and transport is driven by the proton motive force. 
(45). 
In the case of non-lipoproteins, Sec or Tat signal peptides are cleaved by signal peptidase 
(SPase) I upon reaching the periplasm to generate the mature proteins (46).  Lipoproteins are also 
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transported across the cytoplasmic membrane by the Sec and Tat systems, and their signal 
peptides are cleaved by SPase II during the lipoprotein maturation process (47). 
 
Figure 1.4 Sec secretion mechanism.  N-terminal Sec secretion signals are recognized either 
during or following translation in the cytoplasm, and targeted to the SecYEG translocon for 
export across the cytoplasmic membrane.  Following translocation, the signal sequence is 


















Figure 1.5 Tat secretion mechanism.  Pre-folded polypeptides containing N-terminal Tat signal 
sequences are transported across the cytoplasmic membrane by the TatABC complex, and a 




 Gram-positive bacteria, lacking an enclosed periplasmic space, often have membrane-
anchored lipoprotein versions of proteins that are soluble in the periplasmic space of Gram-
negative organisms (50).  This group includes several β-lactamase enzymes, in organisms such 





BRO β-lactamase of the Gram-negative organism Moraxella catarrhalis has also been shown to 
be a lipoprotein, suspected to have been acquired from a Gram-positive source (52). 
 Lipoprotein precursors in both Gram-negative and Gram-positive organisms contain a 
characteristic amino acid motif, termed the lipobox, within a Sec or Tat signal sequence.  The 
lipobox consensus is [LVI] [ASTVI] [GAS] C, where the cysteine residue is absolutely essential 
for lipidation (47).  After the preprolipoprotein is translocated across the cytoplasmic membrane, 
the lipobox is recognized by the lipoprotein diacylglyceryl transferase enzyme (Lgt), which adds 
a diacylglycerol to the cysteine via a thioether bond, to generate a prolipoprotein (50).  The 
lipoprotein signal peptidase (Lsp), also known as Spase II, then removes the signal sequence, 
leaving the acylated cysteine at the N-terminus.  In most Gram-positive bacteria this product 
constitutes a mature lipoprotein, which remains anchored in the outer leaflet of the cytoplasmic 
membrane.  In Gram-negative organisms, the lipoprotein N-acyl transferase (Lnt) enzyme adds a 
third fatty acid to the N-terminal cysteine via an amide linkage (47), forming the mature 
lipoprotein, which can then either remain in the outer leaflet of the inner membrane, or be 
transported to either leaflet of the outer membrane by the lipoprotein localization (Lol) pathway 





Figure 1.6 Prokaryotic lipoprotein biosynthesis.  Bacterial pre-prolipoproteins contain a 
lipobox, including the critical cysteine residue, which is modified with a diacylglycerol.  After 
diacylglycerol addition, the signal sequence is cleaved by lipoprotein signal peptidase.  This 
reaction can be specifically inhibited by globomycin.  In Gram-positive bacteria this cleavage 
results in mature lipoprotein.  In Gram-negative bacteria mature lipoprotein formation requires 





1.7 The PenA β-lactamase 
 The B. pseudomallei genome encodes several β-lactamases (4, 53).  While some research 
has examined a Class D oxacillinase (54, 55), the most studied β-lactamase from B. pseudomallei 
is PenA, which has been implicated in clinical resistance to ceftazidime and amoxicillin-
clavulanate (22-26).  The penA gene is highly conserved among B. pseudomallei strains, and has 
homologues across other species of Burkholderia (56).  Wild-type PenA confers resistance to 
many older β-lactam antibiotics, including amoxicillin, ampicillin, and carbenicillin (21), but 
clinically significant ceftazidime resistance is only achieved through certain amino acid changes 
that modify the substrate specificity, or overexpression of the wild-type gene (21-26).  Similarly, 
wild-type PenA is inhibited by clavulanic acid, allowing amoxicillin-clavulanate to be used for 
treatment of melioidosis, but a point mutation changing the serine at position 72 (Ambler 
numbering [57]) to a phenylalanine results in a clavulanic acid resistant enzyme (21, 23).  While 
relatively rare, it is not surprising that these penA mutations conferring resistance to ceftazidime 
and amoxicillin-clavulanic acid have been found in clinical isolates, given the strong selection 
pressure and lengthy melioidosis treatment period. 
 Rholl et. al. demonstrated that PenA-mediated resistance requires secretion of PenA by 
the Tat secretion system.  Both a strain lacking the tatABC genes, and one with a PenA R8A 
amino acid change had β-lactam susceptibility phenotypes similar to a strain completely lacking 
penA (21).  Tat-secreted β-lactamases have also been identified in Mycobacterium tuberculosis 
(42), Stenotrophomonas maltophilia (41), Xanthomonas campestris (44), Yersinia entercolitica, 
and Photorhabdus asymbiotica (43).  Interestingly, the BlaA β-lactamase from Yersinia 
entercolitica is the closest homologue to PenA outside of Burkholderia species. 
 It has been suggested that PenA is membrane-associated (21, 58).  While an example of a 
membrane-bound lipoprotein β-lactamase has been shown in Gram-negative Moraxella 
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catarrhalis (52), such membrane-associated β-lactamases are generally found in Gram-positive 
organisms (51), while Gram-negative β-lactamases are usually found in the periplasmic space.  
Rholl et. al. failed to show PenA in periplasmic fractions from B. pseudomallei, but those 
experiments had no control to show if any periplasmic proteins were actually being extracted 
(21). 
 
1.8 Hypothesis and Research Aims 
 The purpose of this study was to examine the sub-cellular localization of the PenA β-
lactamase in B. pseudomallei.  Our hypothesis was that in B. pseudomallei, PenA is a Tat-
secreted periplasmic enzyme, whose cellular localization can be determined using appropriate 
methods and controls. 
 The specific aims of this study were: 
1) To evaluate different methods for extracting periplasmic proteins from B. 
pseudomallei using a well-characterized periplasmic marker protein. 






MATERIALS AND METHODS 
 
2.1 Bacterial strains and growth conditions 
 Bacterial strains are listed in Table 2.1.  Bacteria were routinely cultured in Lennox LB 
(MO BIO Laboratories, Carlsbad, CA) at 37°C.  Bp82-derived strains were grown in media 
supplemented with 80 μg/ml adenine.  Antibiotics were used at the following concentrations: 100 
μg/ml ampicillin (Ap) and 35 μg/ml kanamycin (Km) for E. coli and 1,000 μg/ml Km and 2,000 
μg/ml zeocin (Zeo) for B. pseudomallei.  YT media (65) with 15% sucrose and 50 μg/ml X-Gluc 
(Gold Biotechnology, Saint Louis, MO) was used for resolution of merodiploids during allelic 
exchange.  For long-term storage, overnight cultures were mixed with sterile glycerol to a final 
concentration of 20% and frozen at -80°C. 
 
Table 2.1 Bacterial strains used in this study 
 
 
Strain Description Source 
E. coli 
DH5α Cloning strain (59) 
DH5α(λpir+) Cloning strain Schweizer lab collection 
MC4100 Wild-type strain (60) 
B. pseudomallei 
Bp82 1026b ∆purM (61) 
Bp82.11 Bp82 ∆penA (21) 
Bp82.22 Bp82.11::mini-Tn7T-FKM-Ptac-penA D. Rholl, unpublished 
Bp82.75 Bp82::mini-Tn7T-FKM-PS12-phoA This study 
Bp82.101 Bp82.75 ∆(wcbR-A)::Zeo This study 
Bp82.143 Bp82 PenA C23S This study 
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2.2 DNA techniques 
 Plasmids and oligonucleotide primers are listed in Tables 2.2 and 2.3, respectively.  
Plasmid DNA was isolated from E. coli using the GeneJET Plasmid Miniprep Kit (Thermo 
Fisher Scientific, Waltham, MA).  Nucleic acid samples were quantified using a NanoDrop 1000 
(Thermo Fisher Scientific, Waltham, MA).  Genomic DNA to be used as a template for 
polymerase chain reaction (PCR) was extracted by boiling a single colony picked from an agar 
plate in 50 μl deionized water (diH2O) for 10 min, and centrifuging for 2 min at 12,000 x g to 
precipitate cellular debris.  5 μl of supernatant was used as template in a 50 μl PCR reaction. 
 PCR was performed using either standard Taq DNA Polymerase (New England Biolabs, 
Ipswich, MA) for routine PCR, or Platinum Taq DNA Polymerase High Fidelity (Invitrogen, 
Carlsbad, CA) for cloning or sequencing, according to the manufacturer’s instructions, using 
custom oligonucleotide primers purchased from Integrated DNA Technologies (Coralville, IA).  
PCR products were purified and visualized by agarose gel electrophoresis with ethidium 
bromide, and extracted using the Sigma GenElute Gel Extraction Kit (Sigma-Aldrich, Saint 
Louis, MO) when required. 
 The pGEM-T Easy Vector System (Promega, Madison, WI) was used to TA-clone PCR 
products, according to the manufacturer’s instructions.  All newly constructed plasmids were 
confirmed by restriction digest and DNA sequencing (performed at the Colorado State 
University Proteomics and Metabolomics Facility, Fort Collins, CO). 
Restriction digests were performed using enzymes from New England Biolabs (Ipswich, 
MA) according to the manufacturer’s instructions.  After restriction enzyme digestion, DNA 
fragments were separated by agarose gel electrophoresis, visualized with ethidium bromide, and 
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fragments were extracted using the Sigma GenElute Gel Extraction Kit (Sigma-Aldrich, Saint 
Louis, MO).  Ligations were performed using T4 DNA Ligase (Invitrogen, Carlsbad, CA). 
 Plasmids were transformed into chemically competent E. coli, as previously described 
(62).  Plasmids were introduced into B. pseudomallei by electroporation (63). 
 
 Table 2.2 Plasmids used in this study  
Abbreviations: Ap, ampicillin; Km, kanamycin, Zeo, zeocin; r, resistant. 
Plasmid Description Source 
pGEM-T Easy Apr; TA cloning vector Promega 
pTNS3 Apr; helper plasmid encoding the Tn7 site-specific 
transposition pathway 
(64) 
pEXKm5 Kmr; allelic exchange plasmid (65) 
pPS2358 Apr; pGEM-T Easy-∆(wcbR-wcbA)::Zeo T. Mima, 
unpublished 
pPS2669 Kmr; pUC18T-mini-Tn7T-FKM-PS12 B. Kvitko, 
unpublished 
pPS2712 Kmr; pEXKm5-penA; contains C218A SNP (21) 
pPS2921 Apr; pGEM-T Easy-phoA; pGEM-T Easy with 1,435 bp PCR 
product containing the phoA gene amplified from E. coli 
MC4100 genomic DNA using primers 2390 + 2391 
 
This study 
pPS2926 Kmr; pUC18T-miniTn7T-FKM-PS12-phoA; a 1,525 bp ZraI x 
SacI fragment from pPS2921 containing phoA was ligated 
into SmaI + SacI-linearized pPS2669 
 
This study 
pPS3066 Kmr; pEXKm5-∆(wcbR-wcbA)::Zeo; a 2,454 bp EcoRI 
fragment from pPS2358 containing the ∆(wcbR-wcbA)::Zeo 
cassette was ligated into the EcoRI site of pEXKm5 
 
This study 
pPS3092 Kmr; pEXKm5-penA C23S; mutagenic primer 2594 was used 
to change penA nucleotide 67 from T to A, providing a C23S 
substitution, and mutagenic primer 2482 was used to change 





Table 2.3 Oligonucleotide primers used in this study 
Primer Sequence Source 
Cloning 
1687 5’-GGATCCGACGAGAGCTGATACGCTAGa (21) 
1712 5’-AAGCTTATACCGGCATCGTTTCGCTG (21) 
2390 5’-CATGGAGAAAATAAAGTGAAACAAAGC This study 
2391 5’-GGTTTTATTTCAGCCCCAGAG This study 
Mutagenic primers 
2482 5’Phos/-GCGACGAGCGTTTCCCGTTCTGCAGCACATCb This study 
2594 5’Phos/-TGATCGGCGCCAGCGCGCCGCTG This study 
Capsule knockout screening 
536 5’- TCCGCTGCATAACCCTGCTTC (66) 
537 5’- CAGCCTCGCAGAGCAGGATTC (66) 
1664 5’- GTGTTCGCGTACAGCATGTC T. Mima, unpublished 
1716 5’- CTGCAGTACATCCGGCACTA T. Mima, unpublished 
1717 5’- GGGTGTATTCGGCATGAGTC T. Mima, unpublished 
1718 5’- CTTGCGACGGTTCAGAAAGT T. Mima, unpublished 
1719 5’- GAAAAGCCGCCAGTATGTTC T. Mima, unpublished 
1721 5’- AAGGTGTTTGACCAGTTCCG T. Mima, unpublished 
Tn7 integration confirmation 
TN7L 5’-ATTAGCTTACGACGCTACACCC (64) 
BPGLMS1 5’-GAGGAGTGGGCGTCGATCAAC (64) 
BPGLMS2 5’-ACACGACGCAAGAGCGGAATC (64) 
BPGLMS3 5’-CGGACAGGTTCGCGCCATGC (64) 
RT-qPCR 
2077 5’-GTTCTGCAGCACATCCAAGA (21) 
2078 5’-CGGTGTTGTCGCTGTACTGA (21) 
Bp23S-F 5’-GTAGACCCGAAACCAGGTGA (18) 
Bp23S-R 5’- CACCCCTATCCACAGCTCAT (18) 
aUnderline indicates a newly generated restriction enzyme cleavage site. 
bBold indicates introduced point mutations. 
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2.3 Strain construction 
 Mutant Bp82-based strains were constructed using the previously published mini-Tn7 
and pEXKm5 systems (64, 65).  Briefly, the pEXKm5 system was used to generate allelic 
exchange mutants, and the mini-Tn7 transposon was used to insert sequence at a known, non-
disruptive site in the chromosome. 
 
2.3.1 Construction of strains with mini-Tn7 insertions 
 Stable, single-copy gene insertions at a non-disruptive site in the chromosome were 
achieved using the mini-Tn7 system (64).  The E. coli phoA gene was directionally cloned into 
pPS2669 (Figure 2.1), which contains, between Tn7L and Tn7R flanks, a FRT-flanked Kmr 
marker (FKM) and the promoter from the B. thailandensis ribosomal S12 protein-encoding gene 
(PS12), so that phoA was expressed constitutively from PS12.  Specific plasmid construction 
details are found in Table 2.2. 
These pUC18T-mini-Tn7T-based constructs were introduced into Bp82 and/or Bp82.11 
using the helper plasmid pTNS3.  The pUC18T-based plasmids contain a ColE1 origin of 
replication, and pTNS3 contains an R6K origin of replication, neither of which supports plasmid 
replication in Burkholderia spp (64, 65).  pTNS3 supplies the tnsABCD genes encoding the Tn7 
site-specific transposition pathway, which inserts any sequence between Tn7L and Tn7R flanks 
into the bacterial chromosome at an attTn7 site, usually located downstream of a glmS gene (67). 
 Bacteria containing Tn7 insertions were selected for kanamycin resistance, since for the 
Kmr marker to be maintained it must have been chromosomally integrated.  Because B. 
pseudomallei has three glmS genes, there are three possible Tn7 insertion sites.  Integrants were 
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screened by PCR using primer TN7L paired with BPGLMS1, BPGLMS2, and BPGLMS3, and 












Figure 2.1: Map of mini-Tn7 vector pPS2669. The sequence between the Tn7L and Tn7R 
flanks, which can be transposed into the B. pseudomallei genome, contains a FRT-flanked nptII 
gene conferring kanamycin resistance, T0 and T1 transcriptional terminators, and the PS12 
promoter.  Genes of interest can be cloned downstream of PS12 for constitutive expression using 
the unique EcoRI, SmaI, and SacI restriction sites.  The ColE1 replicon allows replication in E. 




2.3.2 Construction of mutants by allelic exchange 
For construction of Bp82.143, the PenA C23S point mutation was introduced into 
Bp82.11 using the pEXKm5 allelic exchange system (65).  pPS3092 (Figure 2.2) was 
electroporated into Bp82.11 and the transformation mixture was plated on YT media containing 
adenine, kanamycin, and X-Gluc.  The kanamycin selected for merodiploids with the plasmid 
integrated in the chromosome through homologous recombination.  Merodiploids also produced 
the β-glucuronidase enzyme encoded by the gusA gene on pEXKm5, which cleaves the indicator 
X-Gluc, resulting in a blue colony appearance. 
Merodiploids were then resolved by growth on YT media containing adenine, 15% 
sucrose, and X-Gluc.  The sucrose prevented growth of merodiploids, due to the sacB gene on 
the pEXKm5 backbone, encoding levansucrase from Bacillus subtilis.  However, bacteria that 
underwent a second homologous recombination event to excise the plasmid backbone (including 
sacB, gusA, and the KmR marker), were sucrose resistant and white in the presence of X-Gluc.  
These resolved clones were confirmed to be kanamycin-susceptible, and screened by PCR and 
Sanger sequencing (with primers 1687 and 1712) to determine whether the desired penA allele 
had been introduced and replaced the corresponding wild-type sequence.  A confirmed mutant 
strain (Bp82.143) was frozen for future use. 
Strain Bp82.101 (Bp82.75∆(wcbR-A)) was also created with a pEXKm5-based plasmid 
(pPS3066, Figure 2.3) but because the parental strain, Bp82.75, was already Kmr, and the 
∆(wcbR-A) knockout cassette contained a Zeor marker, recombinants were selected with zeocin, 
rather than kanamycin.  Following sucrose resolution, zeocin resistant clones were PCR screened 
for the absence of wcbB and gmhA genes from the deleted operon, presence of the Zeor marker, 
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and absence of oriT found on the pEXKm5 backbone using primer pairs 1716 + 1717, 1718 + 











Figure 2.2  Map of the PenAC23S allele replacement plasmid pPS3092.  The nptII gene, 
conferring kanamycin resistance allows for selection of merodiploids, the Bacillus subtilis sacB 
gene allows for counter-selection in the presence of sucrose, and gusA, encoding E. coli β-
glucuronidase, allows colorimetric screening with X-Gluc.  The ColE1 replicon allows 
replication in E. coli, but not B. pseudomallei, and oriT allows for conjugal plasmid transfer.  
The penA gene on this plasmid contains a point mutation that changes amino acid 23 from a 

















Figure 2.3 Map of Δ(wcbR-A) gene replacement vector pPS3066.  The nptII gene, conferring 
kanamycin resistance allows for selection of merodiploids, sacB allows for counter-selection in 
the presence of sucrose, and gusA allows colorimetric screening with X-Gluc.  The ColE1 
replicon allows replication in E. coli, but not B. pseudomallei, and oriT allows for conjugal 






2.4 Extraction of periplasmic proteins  
The PeriPreps Periplasting Kit from EpiCentre Biotechnologies (Madison, WI) was used 
according to the manufacturer’s instructions.  Cells from a 1 ml bacterial culture grown 
overnight were harvested by centrifugation at room temperature for 30 sec at 14,000 x g, 
resuspended in 50 μl PeriPreps Periplasting Buffer, and incubated for 5 min at room temperature.  
50 μl ice cold water was added and mixed by inversion.  The suspension was incubated for 5 min 
on ice, and then centrifuged for 2 min at 14,000 x g at room temperature.  Supernatants, 
containing periplasmic fractions, were removed to clean tubes.  If required, spheroplastic 
proteins were prepared by resuspending the remaining pellets in 100 μl of PeriPreps Lysis Buffer 
with OmniCleave Endonuclease, and 1 μl of 1 M MgCl2 was added, mixed by inversion, and 
incubated for 5 min at room temperature.  Cell debris was collected by centrifugation at room 
temperature for 5 min at 14,000 x g.  Supernatants, containing spheroplastic fractions, were 
transferred to new tubes, and 2 μl 500 mM EDTA was added. 
 Cold osmotic shock was performed according to the method of Higgins and Hardie (68).  
0.5 ml of 0.5 M Tris pH 7.8 was added to 5 ml of overnight cultures and the mixture was 
incubated for 10 min at room temperature.  Cells were collected by centrifugation at 2,500 x g 
for 10 min at room temperature.  Pellets were resuspended in 0.8 ml of sucrose solution (30 mM 
Tris pH 7.8; 40% sucrose; 2 mM EDTA), incubated with shaking for 10 min at 30°C, and 
centrifuged for 30 sec at 14,000 x g at room temperature.  Pellets were rapidly resuspended in 0.5 
ml ice cold water, incubated on ice for 10 min, and the suspensions were centrifuged at 14,000 x 
g for 5 min at 4°C.  Supernatants (periplasmic fractions) were removed and stored at -20°C. 
 Chloroform shock treatment was performed based on the method of Ames et. al. (69).  
Cells were collected from 2 ml of overnight cultures by centrifugation for 30 sec at 14,000 x g at 
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room temperature.  Pellets were resuspended in approximately 20 μl of residual media, 20 μl of 
chloroform was added, and the cell suspensions were vortexed periodically while incubating at 
room temperature for 15 min.  200 μl of 10 mM Tris pH 8 was added, followed by centrifugation 
at 6,000 x g for 20 min at room temperature.  The top, aqueous layers were removed as 
periplasmic fractions and stored at -20°C. 
 
2.5 Membrane fractionation 
 Total membrane fractions were prepared from 10 ml of overnight cultures.  Cells were 
collected by centrifugation at 2,500 x g for 10 min at 4°C, and resuspended in 5 ml diH2O.  They 
were then lysed by sonication on ice.  A Sonics Vibracell VC750 sonicator (Newtown, CT) was 
used at 30% amplitude, using 4 cycles of 1 sec pulses for 1 min followed by a 30 sec pause.  Cell 
debris was pelleted by centrifugation at 2,500 x g for 10 min at 4°C.  Supernatants were 
transferred to new tubes and centrifugation was repeated.  The resulting supernatants, containing 
cell lysates, were spun for 1 hr at 30,000 rpm at 4°C in a Sorvall WX Ultra 100 ultracentrifuge 
(Thermo Fisher Scientific, Waltham, MA), using a TH-641 swinging bucket rotor.  Supernatants, 
containing cytoplasmic and periplasmic proteins, were removed to new tubes, and the membrane 
pellets were resuspended in 1 ml of diH2O and frozen at -20°C. 
 
2.6 Phase separation of membrane proteins using Triton X-114  
 Total membranes were prepared as described above, but instead of water, membrane 
pellets were resuspended in 150 μl 4% Triton X-114 (TX-114) in PBS, transferred to 
microcentrifuge tubes, rocked overnight at 4°C, and centrifuged for 1 hr at 25,000 x g, 4°C.  
Supernatants were moved to new tubes and stored at 4°C, while pellets were resuspended in 150 
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μl 4% TX-114 in PBS, rocked for 1 hr at 4°C, and centrifuged as above.  Supernatants were 
combined with those obtained from the overnight extraction, incubated at 37°C for 1 hr with 
occasional rocking, and centrifuged for 1 hr at 25,000 x g, 37°C.  Upper (aqueous) phases were 
removed, and an equal volume of ice cold PBS was added to return the TX-114 concentration to 
4%.  The 37°C incubation and centrifugation steps were repeated twice.  9 volumes of ice cold 
acetone were added to final detergent phases and mixtures were incubated at -20°C overnight.  
Acetone precipitates were centrifuged for 1 hr at 25,000 x g at 4°C, supernatants were decanted, 
pellets were resuspended in 150 μl ice cold acetone, and centrifugation was repeated.  After 
acetone supernatants were decanted, pellets were air dried completely, resuspended in 200 μl 
diH2O, and frozen at -20°C. 
 
2.7 Detection of proteins by Western blot 
 Cellular fractions were diluted 1:1 in 2X Laemmli sample buffer (65.8 mM Tris-HCl, pH 
6.8, 2.1% SDS, 26.3% glycerol, 0.01% bromophenol blue, 5% β-mercaptoethanol, Bio-Rad 
Laboratories, Hercules, CA), boiled for 10 min, cooled, and separated on 12% polyacrylamide 
Tris-glycine SDS-PAGE gels for approximately 1.5 hr at 200 volts.  Proteins were transferred to 
PVDF membranes using a Bio-Rad Trans-Blot SD semi-dry cell (Bio-Rad Laboratories, 
Hercules, CA).  Membranes were blocked with 4% BSA in TBS-T (20 mM Tris, 500 mM NaCl, 
0.05% Tween 20, pH 7.5) rocking for one hour at room temperature, or overnight at 4°C.  Blots 
were washed twice for 5 min each with water, then stained with primary antibody (see Table 2.4) 
diluted in blocking solution for 1 hr with rocking at room temperature.  Blots were washed three 
times, 5 min each with TBS-T, then stained with secondary antibody for 30 min, rocking at room 
temperature.  Blots were washed 3 times with TBS-T and twice with water (5 min per wash).  1 
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ml of Novex ECL chemiluminescent substrate (Life Technologies, Carlsbad, CA) was added, 
and rocked for 1 min.  Blots were imaged on a ChemiDoc XRS (Bio-Rad Laboratories, Hercules, 
CA). 
 
Table 2.4 Antibodies used for Western blot analyses 
Antigen Type Dilution Source 
E. coli PhoA Mouse monoclonal 1:1,000 Life Technologies, Carlsbad, CA 
B. pseudomallei PenA Rabbit polyclonal 1:1,000 (21) 
E. coli RpoB Mouse monoclonal 1:2,000 Neoclone, Madison, WI 
B. pseudomallei Omp85 Mouse polyclonal 1:500 (70) 
Mouse IgG Goat polyclonal, HRP conjugate 1:2,500 Promega, Madison, WI 
Rabbit IgG Goat polyclonal, HRP conjugate 1:2,500 Promega, Madison, WI 
 
2.8 Protein quantification 
The protein content of samples was quantified using the Pierce BCA Protein Assay 
Reagent kit (Thermo Fisher Scientific, Waltham, MA).  BSA standards were made by serially 
diluting the 2 mg/ml stock in the same diluent as samples (diH2O or 10 mM Tris pH 8) from 320 
μg/ml to 5 μg/ml.  25 μl of blanks (diluent only), standards and samples were aliquotted into a 
microtitre plate wells in duplicate or triplicate, and 200 μl of Working Reagent was added to 
each well.  After incubating 30 min at 37°C and cooling to room temperature, the A570nm of each 
well was read using a Multiskan Spectrum plate reader (Thermo Fisher Scientific, Waltham, 
MA).  Protein concentrations were calculated using Revelation Data Processing software (Dynex 





2.9 Enzyme assays 
 Alkaline phosphatase activity was detected using the colorimetric substrate p-
nitrophenylphosphate (pNPP).  In microtitre plates, 20 μl of cellular fractions were diluted in 180 
μl 10 mM Tris pH 8.0, and 4 μl of 40 mM pNPP (Sigma-Aldrich, Saint Louis, MO) was added 
and mixed by pipette.  Samples were incubated 30 min at 37°C, and the A410nm was read on a 
Multiskan Spectrum plate reader (Thermo Fisher Scientific, Waltham, MA).  Samples were 
assayed in duplicate, and alkaline phosphatase activity was calculated as (average sample A410nm 
- average blank A410nm)/(A600nm starting culture x ml culture used).  Each assay was repeated in 
three separate technical replicates. 
 β-lactamase enzymatic activity was detected using the colorimetric substrate nitrocefin.  
In microtitre plates, 200 μl of 50 μg/ml nitrocefin (TOKU-E, Bellingham, WA) in 100 mM 
sodium phosphate buffer (pH 7) was added to 20 μl of cellular fractions, mixed by pipette, and 
incubated 30 min at 37°C.  A486nm was read with a Multiskan Spectrum plate reader 
(ThermoFisher Scientific, Waltham, MA), and β-lactamase activity from duplicate sample wells 
was calculated as (average sample A486nm - average blank A486nm)/μg protein.  Each assay was 
repeated in three separate technical replicates. 
 
2.10 Reverse transcriptase quantitative real time PCR (RT-qPCR) 
 Overnight cultures were sububcultured into LB + adenine, and upon reaching log phase 
(OD600 between 0.6 and 0.8), RNA was extracted from 1 ml of culture using the Qiagen RNeasy 
RNA Protect Mini Bacteria kit according to manufacturer’s instructions (Qiagen, Germantown, 
MD).  RNA was quantified with a NanoDrop 1000 (Thermo Fisher Scientific, Waltham, MA), 
and 1 µg was treated with DNaseI (Thermo Fisher Scientific, Waltham, MA).  cDNA was 
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synthesized using the Superscript III First Strand Synthesis System (Invitrogen, Carlsbad, CA).  
qPCR was then performed on an iCycler iQ instrument (Bio-Rad Laboratories, Hercules, CA) 
with SYBR GreenER qPCR SuperMix (Invitrogen, Carlsbad, CA) with primers 2077 and 2078 
to amplify penA derived cDNA and Bp23S-F and Bp23S-R to amplify 23S ribosomal RNA 
derived cDNA.  Each sample was assayed in technical triplicate, melt curve analysis showed 
clean amplification, and control reactions with no template, or template untreated with reverse 
transcriptase showed no amplification.  penA transcript levels were normalized to the 23S rRNA 
gene, and expressed as fold change relative to wild-type Bp82. 
 
2.11 14C-palmitic acid labeling 
 10 ml cultures were grown to mid-log phase in in M9 minimal medium (71) with 10 mM 
glucose, 80 μg/ml thiamine and 80 μg/ml adenine.  Cells were harvested by centrifugation at 
2,000 x g for 15 min and resuspended in 1 ml of fresh growth media.  5 μCi of 14C-palmitic acid 
(American Radiolabeled Chemicals, Saint Louis, MO) was added and the cell suspension was 
incubated at 37°C for 2 hr.  Labeled cells were harvested by centrifugation at 2,000 x g for 30 
min, and proteins were extracted with three washes with 5 ml chloroform/methanol.  The final 
pellet was dried under a N2 stream, resuspended in 100 μl Laemmli electrophoresis buffer and 
boiled.  Samples were analyzed by electrophoresis on a 4-15% gradient SDS-PAGE gel (Bio-
Rad, Hercules, CA), the gel was dried, and labeled proteins were imaged by phosphorimaging. 
 
2.12 Globomycin treatment 
PenA expression was induced by adding IPTG to two 1 ml cultures of Bp82.22 at OD600 
0.6.  One culture was treated with 250 μg globomycin (10 mg/ml in DMSO [Sigma-Aldrich, 
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Saint Louis, MO]), and the other with an equal volume of DMSO only, as a control.  Cultures 
were incubated for one hour at 37°C.  The OD600 was measured again, and cells from 0.5 ml of 
the cultures were pelleted by centrifugation and resuspended in Laemmli electrophoresis buffer.  
Samples were then separated by SDS-PAGE and examined by Western blot, as described above. 
 
2.13 MALDI-TOF mass spectrometry 
 Membrane fractions were prepared as described above from cultures of Bp82.22 grown 
with 1mM IPTG to induce penA expression, and Bp82.11.  After resuspension in 1 ml diH2O, 
these membrane samples were washed once with 8 volumes of ice cold acetone, incubated at -
20°C overnight, and pelleted by 27,000 x g for 1 hour at 4°C.  Pellets were air-dried and 
resuspended in 50 μl 50% acetonitrile 0.1% trifluoroacetic acid.  1 μl of each sample was mixed 
with 1 μl 10 mg/ml sinapinic acid matrix on the MALDI-TOF target plate and allowed to air-dry 
overnight.  The samples were then analyzed using a Bruker Ultraflex II MALDI-TOF/TOF 






3.1 Evaluation of periplasmic fractionation methods 
 In order to determine the sub-cellular localization of PenA, we developed methods for 
generating controlled subcellular fractions from B. pseudomallei.  Specifically, a known 
periplasmic marker protein was necessary to test our hypothesis that PenA is a periplasmic 
protein. 
 
3.1.1 Construction of a Bp82 reporter strain expressing E. coli PhoA 
A control strain was generated that constitutively expresses the E. coli phoA gene from 
the B. thailandensis ribosomal S12 protein promoter (PS12), for the purpose of comparing 
different methods of extracting periplasmic protein from B. pseudomallei. 
E. coli alkaline phosphatase (PhoA) is a well-characterized periplasmic protein (72), 
whose activity in the periplasm has been utilized in various reporter systems (73-76).  In 
addition, alkaline phosphatase activity can easily be detected and quantified using the 
colorimetric substrate pNPP. 
The mini-Tn7T-FKM-PS12-phoA construct was introduced into Bp82 as described above, 
to generate Bp82.75.  PhoA expression was confirmed by enzyme assay (Figure 3.1) and 
Western blot (Figure 3.2).  Both detection methods show increased expression of alkaline 
phosphatase activity as compared with wild-type Bp82.  The low-level alkaline phosphatase 




3.1.2 Construction of a Bp82 capsule-deficient strain 
 To examine the possibility that the B. pseudomallei polysaccharide capsule might inhibit 
periplasmic extraction, a derivative of Bp82.75 (Bp82 expressing E. coli phoA) was generated 
that lacks 23,098 bp of the wcbR-A capsule synthesis operon.  The knockout cassette was derived 
from pPS2358, with truncated portions of the wcbR and wcbA genes surrounding a zeocin 
resistance marker, and was cloned into pEXKm5 for allelic exchange, as described in Section 
2.3.2.  In the B. pseudomallei genome, the wcbQ, wcbP, wcbO, wcbN, wcbM, gmhA, wcbL, 
wcbK, wcbJ, wcbI, wcbH, wcbG, wcbF, wcbE, wzt2, wcm2, wcbD, manB, wcbC, and wcbB genes 
of the capsular polysaccharide synthesis operon are found between wcbR and wcbA (4, 53).  In 
the resulting mutant strain, Bp82.101, the gmhA and wcbB genes were not detected by PCR, 
while the presence of the Zeor marker was confirmed by both PCR and bacterial growth in the 
presence of zeocin. 
 
3.1.3 Comparison of periplasmic fractionation methods 
 Bp82.75 (Bp82::mini-Tn7T-FKM-PS12-phoA) and Bp82.101 (Bp82.75 ∆(wcbR-A)::Zeo) 
were used to compare several published methods for extracting periplasmic proteins from E. coli.  
Extraction efficiency was assessed by measuring alkaline phosphatase activity in each of the 
extracted fractions.  Wild-type Bp82 was used as a negative control. 
As shown in Figure 3.2, chloroform shock treatment extracted more alkaline phosphatase 
activity from both Bp82.75 and Bp82.101 than either the PeriPreps or cold osmotic shock 
methods, though none of the methods extracted all of the activity seen in whole cells, indicating 
that periplasmic protein extraction was not complete.  In addition, no difference in alkaline 
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phosphatase extraction efficiency was seen between the strains possessing (Bp82.75) or lacking 












Figure 3.1 Alkaline phosphatase activity in Bp82, Bp82.75, and Bp82.101 whole cells and 
periplasmic fractions.  Periplasmic fractions were prepared using the PeriPreps, cold osmotic 
shock, and chloroform shock methods.  Alkaline phosphatase activities are expressed as (average 
sample A410nm - average blank A410nm)/(A600nm starting culture x ml culture used).  Each assay 
was performed in duplicate, and values shown are the averages of two separate assays.  Error 











3.2 Cellular PenA localization 
 Upon establishment of a successful periplasmic extraction method in B. pseudomallei, 
defined sub-cellular fractions were examined for the presence of PenA by Western blot to detect 
the protein, and by enzyme assay for β-lactamase activity. 
 
3.2.1 PenA is not a periplasmic protein 
 Chloroform-extracted periplasmic protein samples were examined by Western blot for 
the presence of PenA and the alkaline phosphatase marker protein (Figure 3.2).  PhoA 
(approximately 50 kD) is present in significant amounts in both whole cell and periplasmic 
fractions from Bp82.75, which is in agreement with alkaline phosphatase enzyme activity in both 
whole cells and periplasmic fractions (Figure 3.1).  No PhoA protein is detectable in extracts 
derived from wild-type Bp82.  The 85 kD outer membrane protein Omp85 and the 150 kD 
cytoplasmic RpoB protein are present in whole cell fractions from all three strains, but absent 
from any of the periplasmic fractions, indicating that periplasmic fractions are free of outer 
membrane and cytoplasmic contamination. 
Whole cell fractions derived from both strains with the wild-type penA gene (Bp82 and 
Bp82.75 [Bp82 expressing E. coli PhoA]) contain a strong ~27 kD PenA band that is absent in 
Bp82∆penA.  However, periplasmic fractions from these strains contain very little PenA protein.  
Furthermore, while β-lactamase activity from PenA is present in wild-type Bp82 whole cell 
fractions (as compared with Bp82∆penA [Bp82.11]), essentially no β-lactamase activity could be 










Figure 3.2  Cellular localization of PenA assessed by Western blot analysis.  Whole cell and 
chloroform-extracted periplasmic fractions derived from Bp82 expressing phoA (Bp82-phoAEC 
or Bp82.75), wild-type Bp82, and Bp82∆penA (Bp82.11) were separated by SDS-PAGE, 
transferred to PVDF membranes, and probed with antibodies against PenA, PhoA, Omp85, and 
















Figure 3.3 Cellular localization of PenA β-lactamase activity.  β-lactamase activity was 
determined in Bp82 and Bp82.11 whole cell and chloroform-extracted periplasmic samples using 
nitrocefin as a substrate.  Activity was calculated as (average sample A486nm - average blank 
A486nm)/μg protein, with protein concentration calculated by BCA assay.  Each assay was 
performed in duplicate, and the values shown are the averages from three separate assays, with 
error bars representing one standard deviation from the mean.  
 
3.2.2 PenA is a membrane associated protein 
 After seeing less than convincing evidence of PenA being located in the periplasm, 
membrane fractions were prepared from wild-type Bp82 and Bp82∆penA.  The presence of PenA 
in these fractions was assessed by Western blot (Figure 3.4) and β-lactamase enzyme assay 
(Figure 3.5).  Large quantities of PenA protein and its corresponding β-lactamase activity were 
detected in whole cell, total membrane, and detergent extracted membrane fractions.  In fact, 





whole cell fraction.  The presence of Omp85 and absence of PhoA in membrane fractions was 










Figure 3.4 PenA membrane localization analyzed by Western blot.  Wild-type Bp82 and 
Bp82∆penA (Bp82.11) whole cell, total membrane and TX-114 extracted samples were 


















Figure 3.5 PenA β-lactamase activity is membrane associated.  β-lactamase activity was 
determined in wild-type Bp82 and Bp82∆penA (Bp82.11) whole cell, total membrane, and TX-
114 extracted samples using nitrocefin as the substrate.  Activity was calculated as (average 
sample A486nm - average blank A486nm)/μg protein, with protein concentration determined by BCA 
assay.  Each assay was performed in duplicate, and the values shown are the averages from three 





3.3 PenA is a lipoprotein 
 The experiments described in section 3.2.2 showed that PenA protein and associated β-
lactamase activity are membrane associated and can be extracted with Triton X-114 (TX-114).  
TX-114 is a nonionic detergent with a low cloud point (77), which has been used to enrich for 
lipoproteins from a variety of bacterial species (78-82).  Following a temperature-based TX-114 
phase separation, lipoproteins, as well as other lipophilic proteins are found in the detergent 
phase, while hydrophilic non-lipoproteins partition to the aqueous phase.  While separation of a 
protein to the TX-114 detergent phase cannot definitively identify it as a lipoprotein, this 
hydrophobic behavior provided additional evidence supporting the model of PenA as membrane-
bound lipoprotein.  Attempts were therefore made to assess whether PenA membrane association 
is a result of post-translational lipid modification. 
 
3.3.1 LipoP software prediction 
 Bacterial lipoproteins contain lipobox motifs that mediate lipid modification and signal 
peptide cleavage, allowing for anchoring to the inner or outer membrane (47).  The online LipoP 
software predicts whether prokaryotic protein sequences contain lipoprotein signal peptides, and 
identifies any signal peptidase (SPase) II cleavage sites (83).  According to LipoP, PenA is likely 
a lipoprotein, with SPase II cleaving between amino acids A22 and C23 (Figure 3.6).  Bacterial 
lipoprotein biosynthesis requires a cysteine residue at the amino-terminal of the mature protein, 
to which a diacylglycerol molecule is covalently attached.  Since the PenA amino terminus 
contains a potential non-canonical lipobox with a conserved cysteine (Cys23), it is highly 
probable that PenA is a lipoprotein and that the post-translational lipid modification occurs at 







Figure 3.6  The predicted PenA signal sequence.  The 29 N-terminal amino acids of PenA are 
shown.  The twin arginines directing PenA Tat secretion are shown in red letters.  The predicted 
non-canonical lipobox is shown in blue letters.  The critical cysteine required for post-
translational lipid modification is marked with an asterisk. 
 
 
3.3.2 Cys23 is required for PenA maturation 
 Based on current understanding of prokaryotic lipoprotein biosynthesis, replacement of 
Cys23 with a different amino acid should prevent the post-translational lipid modification and 
potentially PenA’s membrane association. 
 An isogenic mutant was therefore constructed by allelic exchange that resulted in a single 
amino acid change from cysteine to serine at position 23 of PenA.  The mutant allele was 
introduced from pPS3092 into Bp82.11 to generate Bp82.143, as described in Section 2.3.2.  The 
single mutation to penA was confirmed by DNA sequencing. 
 Surprisingly, while the resulting strain, Bp82.142, had penA transcript levels 
indistinguishable from wild-type Bp82 by qRT-PCR (Figure 3.7), the PenAC23S mutant produced 
neither PenA protein nor β-lactamase activity, as assessed by Western blot analysis of whole 
cells or membranes and enzyme assay (Figure 3.8 and 3.9).  Therefore, it appears that the 
PenAC23S protein is being degraded, indicating that Cys23 is essential for the processing and 










Figure 3.7  The penAC23S mutant gene is transcribed at wild-type levels.  qRT-PCR was 
employed to determine penA transcripts levels in wild-type Bp82, Bp82∆penA (Bp82.11), and 
Bp82 PenAC23S (Bp82.143).  Data shown represent the average expression from three biological 






Figure 3.8 PenA lipidation is required for proper cellular localization.  Western blots of 
whole cells and total membranes from Bp82∆penA (Bp82.11), Bp82 PenAC23S (Bp82.143), and 
wild-type Bp82.  Whole cells and membrane fractions were separated by SDS-PAGE, transferred 
















Figure 3.9  PenA lipidation is required for enzymatic activity.   β-lactamase enzyme assays 
were performed with wild-type Bp82, Bp82∆penA (Bp82.11), and Bp82 PenAC23S (Bp82.143) 
whole cells and total membrane fractions.  Activity was calculated as (average sample A486nm - 
average blank A486nm)/μg protein, with protein concentration determined by BCA assay.  Each 
assay was performed in duplicate, and the values shown are the averages from three separate 











3.3.3 PenA is likely modified by palmitic acid 
 Another means of demonstrating post-translational lipid modification of PenA involves 
incorporation of radioactive fatty acids.  Wild-type Bp82 and Bp82∆penA (Bp82.11) were 
metabolically labeled with 14C-palmitic acid.  Proteins were extracted with chloroform/methanol 
and separated by SDS-PAGE, and the gel was examined for differences in incorporation of the 
14C-palmitic acid between strains that were or were not expressing penA.  The arrow in Figure 
3.10 indicates a radioactive band of approximately 27 kD that appears to be present in Bp82 
samples but not in the ΔpenA strain Bp82.11, though high background makes it difficult to draw 














Figure 3.10  14C-palmitic acid labeling of B. pseudomallei proteins.  Strains Bp82 and 
Bp82.11 were labeled for 2 hr using 14C-palmitic acid.  20,000 dpm and 40,000 dpm of each 
sample were separated by SDS-PAGE and the dried gel was subjected to autoradiography.  The 
red arrow indicates the position of the putative 14C-palmitic acid-labeled PenA lipoprotein. 
 
3.3.4 Globomycin treatment inhibits PenA lipoprotein processing 
Further evidence that PenA is a lipoprotein was obtained by assessing whether inhibition 
of prolipoprotein processing would result in accumulation of PenA prolipoprotein.  Globomycin 
is a peptide antibiotic that specifically inhibits SPase II, the enzyme that removes signal peptides 
from bacterial lipoproteins (84).  Therefore, treatment of bacterial cells with sub-lethal levels of 
globomycin results in an accumulation of uncleaved prolipoproteins.  A Bp82-based strain with 
penA under the control of the inducible Ptac promoter (Bp82.22) was treated with globomycin 





samples were examined by α-PenA Western blot (Figure 3.11).  While a single mature PenA 
band was detected in the untreated control, the globomycin-treated sample contained a slightly 
larger band, representing the PenA proliporotein, in addition to the smaller, mature protein.  
Based on the specific inhibition of SPaseII by globomycin, this provides convincing evidence 









Figure 3.11  Globomycin treatment results in PenA prolipoprotein accumulation.  Whole 
cell samples derived from cultures that were either left untreated or were treated with 
globomycin at the indicated concentration were separated by SDS-PAGE, transferred to a PVDF 






3.3.5 Mass spectrometry indicates post-translational lipid modification of PenA 
Total membrane samples from Bp82∆penA (Bp82.11) and IPTG-induced Bp82.22 
expressing penA from the Ptac promoter were compared using MALDI-TOF mass spectrometry.  
Shown in Figure 3.12, the peak corresponding to the mature PenA protein was identified by its 
presence in the induced sample and absence from Bp82∆penA.  All other peaks, representing 
other membrane proteins, were present in both samples.  Based on the mass to charge ratio 
detected, the molecular weight of the mature PenA molecule is 29,796.547 Da.  Using ExPASy 
online bioinformatics software (85), the molecular weight of the full-length PenA polypeptide 
was calculated to be 31,315.69 Da, while the amino acid sequence of our proposed mature PenA 
lipoprotein, beginning at Cys23, should have a molecular weight of 29,015.93 Da.  The addition 
of a diacylglycerol molecule of ~500 Da and a third, amide-linked fatty acid of ~200-300 Da 
would yield a mature triacylated PenA lipoprotein of ~29,700-29,800 Da, which is reflected in 






Figure 3.12 MALDI-TOF mass spectrometry identification of PenA from total membrane 
fractions.  Total membrane samples from Bp82∆penA (Bp82.11) (blue) and Bp82 expressing 
penA from the Ptac promoter induced with IPTG (green) were analyzed by MALDI-TOF mass 
spectrometry.  The precise molecular weights of the three peaks are labeled, and the peak 









 As the causative agent of melioidosis, B. pseudomallei is a public health concern in terms 
of natural infections in endemic regions of the world, as well as for its potential use as a 
biological weapon.  In combination with its relatively high rates of morbidity and mortality and 
low infectious dose, the intrinsic antibiotic resistance of B. pseudomallei is particularly alarming.  
A variety of resistance mechanisms, including several chromosomal β-lactamases, an 
impermeable outer membrane, and a wide array of efflux pumps, make B. pseudomallei 
impervious to many of the drugs commonly used to treat bacterial infections.  As a result, 
melioidosis treatment options are limited to a small group of antibiotics, which must be 
administered over an extended period of time.  Given the lengthy treatment regimen and the 
resilient nature of B. pseudomallei, it is not altogether surprising that cases of treatment failure 
have been documented, where the organism has developed resistance to the drug used for 
treatment.  Many of these instances of treatment failure have been attributed to mutations in the 
chromosomal β-lactamase PenA, conferring resistance to the front-line drug of choice, 
ceftazidime. 
 While the hydrolysis of ceftazidime by wild-type PenA is very limited and does not 
interfere with treatment, upregulation of the gene or certain amino acid changes that have been 
identified in clinical isolates can render the organism resistant.  Similarly, wild-type PenA is 
susceptible to clavulanic acid inhibition, and therefore amoxicillin-clavulanate can be used as an 
alternative melioidosis treatment.  However, an amino acid change in PenA, or overexpression of 
the β-lactamase confers resistance to amoxicillin-clavulanate. 
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In addition to definitively showing that these changes in PenA drastically alter the β-
lactam susceptibility profile of B. pseudomallei, Rholl et. al. also demonstrated that PenA must 
be transported across the cytoplasmic membrane by the Tat secretion system in order to confer 
resistance (21).  While not unprecedented, this example of a Tat-secreted β-lactamase was 
somewhat unusual.  Furthermore, unlike classic examples of β-lactamase enzymes, the final sub-
cellular destination of PenA was unclear, with varying predictions and reports suggesting it 
might be periplasmic, or could be membrane-associated.  We hypothesized that PenA is indeed 
secreted by the Tat system to the periplasm, and that previous studies were unable to show 
periplasmic localization because the methods used were not suited to B. pseudomallei. 
 To test this hypothesis, strains were generated that expresses the known periplasmic 
protein, PhoA.  Using these B. pseudomallei reporter strains, several methods for extracting 
periplasmic proteins were compared.  While all of these methods have been used successfully 
with E. coli and other Gram-negative organisms, the PeriPreps and cold osmotic shock methods 
proved to be fairly ineffective at extracting periplasmic protein from B. pseudomallei.  
Fortunately, the chloroform treatment method yielded more efficient periplasmic extraction, and 
was chosen for future use.  Periplasmic extraction by any of the methods tested was not 
enhanced by lack of capsular polysaccharide, indicating that the B. pseudomallei capsule is not 
responsible for the differences observed in extraction efficiency compared with other Gram-
negative organisms. 
However, these defined periplasmic protein samples did not contain the high levels of 
PenA that were expected.  Instead, the vast majority of PenA was detected in total membrane 
fractions.  Further experiments have shown that this membrane association is likely due to the 
post-translational addition of lipid molecules to the cysteine residue at position 23 (Cys23) of 
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PenA.  The degradation of a C23S mutant version of PenA suggests that Cys23 is required for 
proper processing of the protein, and TX-114 phase partitioning indicates that the mature PenA 
is lipophilic.  Metabolic labeling of B. pseudomallei with 14C-palmitic acid suggests that palmitic 
acid could be incorporated into PenA.  More definitively, globomycin treatment, which interferes 
with SPase II cleavage of signal peptides from bacterial lipoproteins, resulted in the appearance 
of a larger form of PenA, presumed to be the uncleaved pro-lipoprotein, and the molecular 
weight of mature PenA determined by MALDI-TOF was consistent with a triacylated 
lipoprotein.  This evidence suggests that PenA is a Tat-secreted lipoprotein. 
Future work will include purifying PenA by immunoprecipitation or epitope tag 
purification in order to more definitively show specific 14C-palmitic acid labeling.  Alternative 
methods for confirming post-translational lipid modification of PenA include mass spectrometry 
and acylbiotin-exchange chemistry. 
It is intriguing that replacement of Cys23 of PenA with a serine residue results in 
degradation of the protein, presumably because it is no longer recognized by the lipoprotein 
synthesis proteins.  Replacement of Ile20 with an alanine would convert the signal sequence to 
one that should be recognized by SPaseI, potentially allowing this doubly mutated version of 
PenA to be processed by the cellular machinery involved in maturation of non-lipidated Tat-
secreted proteins.  Consequently the I20A amino acid change might rescue the PenAC23S protein.  
If so, the resulting protein would be expected to localize to the periplasm like a more typical β-
lactamase, and it would be interesting to compare the β-lactam susceptibility profile of such a 
mutant with the wild-type strain. 
Additionally, further research could be done to show specific inner or outer membrane 
localization of PenA, though a means of detecting a defined inner membrane marker protein in 
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B. pseudomallei must be developed first.  Lipoproteins in Gram-negative bacteria are transported 
to the outer membrane by the lipoprotein localization (Lol) system or retained in inner membrane 
by so called “Lol-avoidance” signals.  In E. coli the inner membrane retention signal involves an 
aspartate residue at position +2 of the mature protein, while in P. aeruginosa lipoproteins are 
retained in the inner membrane by lysine and serine at positions +3 and +4 (50).  As PenA does 
not have either of these canonical signals following Cys23 (see Figure 3.6), it would be predicted 
to localize to the outer membrane.  However, the variability of Lol-avoidance signals between 
species dictates experimental confirmation. 
There are well-documented examples of both Tat-secreted β-lactamases (41-44) and 
lipoprotein β-lactamases (51, 52).  Evidence of Tat-secreted lipoproteins is emerging as well (86-
91), though many of these reports rely heavily on bioinformatic predictions and only a few 
examples have been confirmed experimentally.  Therefore, as a Gram-negative Tat-secreted 
lipoprotein β-lactamase, PenA is highly unusual. 
This new understanding of PenA processing and maturation could potentially open the 
door to new treatment options.  The development of PenA-mediated ceftazidime or amoxicillin-
clavulanate resistance during melioidosis treatment might be avoided by treating with an 
inhibitor of Tat secretion or lipoprotein biosynthesis in combination with the antibiotic.  In 
addition, the efficacy of older β-lactams such as penicillin and amoxicillin might be restored 
against B. pseudomallei if used in combination with lipoprotein or Tat inhibitors.  Considering 
that the limited number of antibiotics currently used during the acute phase of melioidosis 
therapy all require intravenous administration, new treatment options, especially ones that could 
potentially be delivered in a less invasive manner, for a shorter duration, or at a lower cost, 
would be extremely helpful. 
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Tat secretion systems have been identified in plants, bacteria, and archaea, but not in 
animal cells.  Similarly, the bacterial lipoprotein biosynthesis pathway is unique to prokaryotic 
organisms.  The lack of either of these systems in animals makes them potential targets for new 
antibiotics.  Two natural products have been identified that inhibit the lipoprotein signal 
peptidase.  Globomycin, which was used in this study, has been around for several decades (84), 
while the so called “TA” antibiotic produced by Myxococcus xanthus has been a more recent 
topic of study (92).  Vasil et. al. recently described an in vitro screen for Tat inhibitors that 
yielded two possible hits (93).  Even if these compounds do not turn out to be ideal antibiotics on 
their own, they might make excellent PenA inhibitors in combination with traditional β-lactam 
antibiotics. 
These findings may also have implications outside the realm B. pseudomallei treatment.  
PenA is the second documented example of a lipoprotein β-lactamase in a Gram-negative 
organism, following the characterization of the BRO enzyme from Moraxella catarrhalis (50).  
As antibiotic resistance continues to emerge as a public health concern, research is likely to 
uncover more diversity among β-lactamase enzymes.  PenA will serve as an example of one such 
β-lactamase whose secretion and processing differ from the classic TEM-1 model enzyme.  In 
terms of more general bacterial physiology, this work demonstrates experimental 
characterization of a Tat-secreted lipoprotein, most descriptions of which thus far have been 
based primarily on bioinformatic predictions. 
 While these results effectively disprove the original hypothesis of PenA being a 
periplasmic enzyme, its classification as a Tat-secreted lipoprotein is novel among characterized 
β-lactamase enzymes.  This provides insight into β-lactamase enzymes in general, as well as 
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LIST OF ABBREVIATIONS 
°C  degrees Celcius 
A410nm  absorbance at 410 nm 
A486nm  absorbance at 486 nm 
A570nm  absorbance at 570 nm 
A600nm  absorbance at 600 nm 
A  alanine 
Ap  ampicillin 
B.  Burkholderia 
BCA  bicinchoninic acid 
bp  base pair(s) 
BSA  bovine serum albumin 
C  cysteine 
cDNA  complementary DNA 
CHCl3  chloroform 
Cys  cysteine 
diH2O  deionized water 
Da  daltons 
dpm  disintegrations per minute 
E.  Escherichia 
EDTA  Ethylenediaminetetraacetic acid 
FKM  FRT-flanked Kmr marker 
FRT  Flp-recombinase target  
61 
 
g  Earth’s gravitational acceleration 
G  glycine 
hr  hour(s) 
HRP  horseradish peroxidase 
I  isoleucine 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
kD  kilodalton 
Km  kanamycin 
Kmr  kanamycin resistance marker 
L  leucine 
M  molar 
MALDI-TOF matrix-assisted laser desorption/ionization time-of-flight 
mg  milligram(s) 
min  minute(s) 
ml  milliliter(s) 
mM  millimolar 
N-  amino- 
nm  nanometer(s) 
P.  Pseudomonas 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
pNPP  p-nitrophenylphosphate 
62 
 
PVDF  polyvinylidene fluroide 
R  arginine 
RND  resistance nodulation and cell division 
rpm  rotations per minute 
RT-qPCR reverse transcriptase real time PCR 
S  serine 
SDS  sodium dodecyl sulfate 
sec  second(s) 
SNP  single nucleotide polymorphism 
SOE  splicing overlap extension 
SPase  signal peptidase 
spp.  species 
SRP  signal recognition peptide 
SS  signal sequence 
T  threonine 
Tat  twin arginine translocase 
TBS  Tris-buffered saline 
TBS-T  0.05% Tween 20 in TBS 
TX-114 Triton X-114 
μg  microgram(s) 
μl  microliter(s) 
V  valine 
WT  wild-type 
63 
 
X-Gluc 5-bromo-4-chloro-3-indolyl-beta-D-glucuronic acid 
Zeo  zeocin 
